- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.15 Å
- Oligo State
- homo-dimer
- Ligands
- 8 x ZN: ZINC ION(Non-covalent)
- 2 x SFG: SINEFUNGIN(Non-covalent)
SFG.5: 16 residues within 4Å:- Chain A: M.138, G.139, W.140, S.174, Y.175, R.199, F.200, N.202, H.203, Y.244, W.249, F.256, T.257, C.258, Q.259
- Ligands: 01.6
8 PLIP interactions:8 interactions with chain A- Hydrogen bonds: A:W.140, A:S.174, A:Y.175, A:R.199, A:N.202, A:H.203, A:H.203, A:Q.259
SFG.11: 16 residues within 4Å:- Chain B: M.138, G.139, W.140, S.174, Y.175, R.199, F.200, I.201, N.202, H.203, Y.244, F.256, T.257, C.258, Q.259
- Ligands: 01.12
12 PLIP interactions:12 interactions with chain B- Hydrophobic interactions: B:Y.175, B:Y.244
- Hydrogen bonds: B:M.138, B:W.140, B:S.174, B:Y.175, B:Y.175, B:R.199, B:H.203, B:H.203, B:Y.244, B:Q.259
- 2 x 01: ~{N}-[(2~{S})-1-[[6-(1-methylpiperidin-4-yl)oxypyridin-3-yl]amino]-1-oxidanylidene-hexan-2-yl]-3-(pyridin-4-ylamino)benzamide
01.6: 18 residues within 4Å:- Chain A: I.99, E.100, D.164, A.167, D.168, D.173, S.174, L.176, F.177, D.178, P.211, R.213, F.242, D.243, Y.244, R.247, F.248
- Ligands: SFG.5
18 PLIP interactions:18 interactions with chain A- Hydrophobic interactions: A:A.167, A:L.176, A:F.242, A:F.242, A:Y.244, A:Y.244, A:Y.244, A:Y.244, A:R.247
- Hydrogen bonds: A:D.168, A:L.176, A:D.178, A:D.178, A:R.213, A:R.213, A:Y.244, A:R.247
- Water bridges: A:F.248
01.12: 17 residues within 4Å:- Chain B: I.99, Y.157, D.164, A.167, D.168, D.173, S.174, Y.175, L.176, F.177, D.178, P.211, R.213, D.243, Y.244, R.247
- Ligands: SFG.11
17 PLIP interactions:17 interactions with chain B- Hydrophobic interactions: B:A.167, B:D.173, B:L.176, B:L.176, B:D.178, B:P.211, B:Y.244, B:Y.244
- Hydrogen bonds: B:L.176, B:D.178, B:D.178, B:R.213, B:R.213, B:Y.244, B:R.247, B:R.247
- pi-Cation interactions: B:R.247
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nishigaya, Y. et al., Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease. Eur.J.Med.Chem. (2025)
- Release Date
- 2025-05-21
- Peptides
- Histone-lysine N-methyltransferase EHMT2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.15 Å
- Oligo State
- homo-dimer
- Ligands
- 8 x ZN: ZINC ION(Non-covalent)
- 2 x SFG: SINEFUNGIN(Non-covalent)
- 2 x 01: ~{N}-[(2~{S})-1-[[6-(1-methylpiperidin-4-yl)oxypyridin-3-yl]amino]-1-oxidanylidene-hexan-2-yl]-3-(pyridin-4-ylamino)benzamide
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nishigaya, Y. et al., Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease. Eur.J.Med.Chem. (2025)
- Release Date
- 2025-05-21
- Peptides
- Histone-lysine N-methyltransferase EHMT2: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B